Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90033


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus paclitaxel and gemcitabine in treating patients with platinum-resistant recurrent ovarian cancer.

Study summary:

OBJECTIVES: - Determine the response rate, progression time, and survival of patients with platinum-resistant ovarian cancer treated with weekly paclitaxel and gemcitabine. - Determine the toxic effects of this regimen in these patients. - Evaluate the toxic effects and safety profile of premedication with steroids with this regimen in these patients. OUTLINE: Patients are stratified according to prior treatment with paclitaxel (none or relapse more than 6 months after paclitaxel versus progressive disease or relapse less than 6 months after paclitaxel). Patients receive dexamethasone IV, then paclitaxel IV followed by gemcitabine IV, for 3 consecutive weeks on days 1, 8, and 15. Treatment is continued every 4 weeks in the absence of disease progression or unacceptable toxicity. All patients are followed until death. PROJECTED ACCRUAL: Approximately 18-35 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically confirmed recurrent ovarian epithelial cancer - Platinum resistant disease defined as: - Progression during the most recent platinum-based chemotherapy OR - Relapse less than 6 months after platinum-based chemotherapy - Measurable or evaluable disease - Elevated CA-125 only allowed - Positive cytology only not eligible PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - SWOG 0-2 Hematopoietic: - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin less than 2 times upper limit of normal (ULN) - AST less than 3 times ULN Renal: - Creatinine no greater than 2 mg/dL Neurologic: - No peripheral neuropathy greater than grade 2 Other: - No other serious medical illness or psychiatric conditions. PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent hematopoietic growth factors Chemotherapy: - See Disease Characteristics - No prior gemcitabine - No prior paclitaxel administered weekly Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified Other: - Recovered from acute toxic effects secondary to prior therapy



Primary Contact:

Study Chair
Agustin Garcia, MD
University of Southern California

Backup Contact:


Location Contact:

Los Angeles, California 90033
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.